BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...
Pregnancy may worsen RP progression, especially in women with USH2A-related RP and Usher syndrome. Parous women showed a 2.74-fold increased risk of severe visual acuity decline compared to ...
Faricimab increased treatment intervals and decreased CST in previously treated nAMD patients, but BCVA remained unchanged. The study included 88 eyes from 73 patients, with a mean follow-up of 30.1 ...
Please provide your email address to receive an email when new articles are posted on . Distance BCVA improved significantly in patients treated with RevitalVision. Forty-six percent of treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results